Trial Profile
A Phase Ib Study Combining Irinotecan With AZD1775, a Selective Wee 1 Inhibitor, in RAS (KRAS or NRAS) or BRAF Mutated Metastatic Colorectal Cancer Patients Who Have Progressed on First Line Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 08 Oct 2020 Status changed from recruiting to completed.
- 30 Oct 2019 Planned End Date changed from 1 Sep 2019 to 1 Sep 2020.
- 16 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.